Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 7;4(11):e006020.
doi: 10.1136/bmjopen-2014-006020.

One lithium level >1.0 mmol/L causes an acute decline in eGFR: findings from a retrospective analysis of a monitoring database

E Kirkham  1 , J Skinner  2 , T Anderson  3 , S Bazire  1 , M J Twigg  4 , J A Desborough  4
Affiliations

One lithium level >1.0 mmol/L causes an acute decline in eGFR: findings from a retrospective analysis of a monitoring database

E Kirkham et al. BMJ Open. .

Abstract

Objectives: Lithium is a mainstay of bipolar disorder treatment, however, there are still differences in opinion on the effects of lithium use on renal function. The aim of this analysis was to determine if there is an association between short-term exposure to various elevated lithium levels and estimated-glomerular filtration rate (eGFR) at ≤3 months, 6 months (±3 months) and 1 year (±3 months) follow-up.

Setting: Norfolk-wide (UK) lithium register and database.

Participants: 699 patients from the Norfolk database.

Primary outcome measures: eGFR change from baseline at ≤3 months, 6 months (±3 months) and 1 year (±3 months) after exposure to a lithium level within these ranges: 0.81-1.0 mmol/L (group 2), 1.01-1.2 mmol/L (group 3) and 1.21-2.0 mmol/L (group 4). The reference group was patients whose lithium levels never exceeded 0.8 mmol/L.

Results: Compared to the reference group, groups 3 and 4 showed a significant decrease in eGFR in the first 3 months after exposure (p=0.047 and p=0.040). At 6 months (±3 months) postexposure group 4 still showed a decline in eGFR, however, this result was not significant (p=0.298).

Conclusions: These results show for the first time that a single incident of a lithium level >1.0 mmol/L is associated with a significant decrease in eGFR in the following 3 months when compared to patients whose lithium levels never exceeded 0.8 mmol/L. It is still not known whether the kidneys can recover this lost function and the impact that more than a single exposure to a level within these ranges can have on renal function. These results suggest that lithium level monitoring should be undertaken at least every 3 months, in line with current UK guidelines and not be reduced further until the impact of more than one exposure to these lithium levels has been fully established.

Keywords: MENTAL HEALTH; NEPHROLOGY.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Process of sample selection.
See this image and copyright information in PMC

References

    1. NICE. National Institute for Health and Care Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical Guideline 38 2006, 2006.
    1. Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. Bipolar Disord 2011;13:219–26. - PubMed
    1. NICE. National Institute for Health and Care Excellence: Early identification and management of chronic kidney disease in adults in primary and secondary care. Clinical Guideline 73 2008, 2008. - PubMed
    1. Severus WE, Kleindienst N, Seemüller F et al. . What is the optimal serum lithium level in the long-term treatment of bipolar disorder—a review? Bipolar Disord 2008;10:231–7. - PubMed
    1. McKnight RF, Adida M, Budge K et al. . Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721–8. - PubMed

LinkOut - more resources